Criteria for inclusions in the study included a positive COVID-19 lab test, hospitalization with fever and cough, and fewer than eight days since the onset of the illness.
The Gilead trial for patients who are severely ill does not include what's known as a control group, so it could be hard to say whether the drug is truly helping patients recover better. The test group was treated with the drug, developed by Gilead Sciences, while the untreated comparison group was not. "We've only had two patients perish".
The report comes less than a week after a small research study revealed that remdesivir is showing early promise in the battle against the coronavirus outbreak. According to a study by the Chicago University Hospital, remdesivir, which was originally developed against Ebola, led to a rapid reduction in fever and a reduction in the symptoms of the lung disease, so that nearly all patients could be discharged in less than a week. "In the scientific community, over decades, we've established that critical review of clinical trials is the best way to determine if the data is strong enough to inform clinical decisions".
Gilead expects to report data from a study testing two regimens of remdesivir in patients with severe disease by the end of April, with data from a study of patients with moderate disease coming in late May. She said it's not at all clear to her if the drug is having an impact.
The World Health Organization (WHO) is also testing remdesivir in a large-scale study called "Solidarity Trial" and comparing it with standard treatments and virus inhibitors from AIDS therapy.
Ever since the Coronavirus outbreak hit the world, global researchers have been searching for a cure and a new report revealed that the Coronavirus patients who are receiving an experimental drug called Remdesivir have been recovering quickly. "I change a patient's meds and the next day they look better, and it could be because I changed their meds, or it could be they were destined to get better anyways for other reasons". "Overall, patients are doing well and have made recoveries, even the sickest of the sick". In a video, where Mullane was reportedly discussing the clinical trial of remdesivir with her colleagues, she said, "Most of our patients are severe and majority are leaving at six days, so that tells us the duration of therapy doesn't have to be 10 days". The discussion was recorded, and Stat obtained a copy of the video. The report doesn't say whether the study is part of WHO's massive coronavirus drug trial.
Researchers have collected information from the first 400 patients enrolled in the trial and Gilead plans to "lock" the data on Thursday, meaning the results could come soon, Stat said. She indicated that data for the first 400 patients in trials would be released within days.
Hyderabad Police Book Jr NTR Fans For Abusing Meera Chopra
In view of the fixed threats, she has additionally lodged a criticism with the National Commission for Women in cyber police. She tweeted to the Hyderabad police with screenshots of all the abusive and intimidating tweets and sought their help.
Aubameyang is "too good" for Arsenal - Jamie Carragher
That's the problem you have when you're trying to get back into the top four and establish yourself as Arsenal are trying to do. Arsenal now occupy ninth place in the Premier League, eight points behind Chelsea, who sit in the final Champions League spot.